SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

EDAP TMS S.A. (FOCL) News

Track canonical SquawkNews coverage tagged to FOCL, EDAP TMS S.A.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol FOCL Asset equity Sector Markets 90 days 6 Last 6.045 Updated Aug 11, 2026, 08:34 PM UTC Open live news feed
L FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Di EQUITY | Aug 11, 2026, 08:34 PM UTC L FOCL - FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 FOCL - FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 EQUITY | Aug 11, 2026, 08:28 PM UTC L FocalTherics Announces Underwritten Public Offering Of ADSs The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the Offering on the same terms and conditions. The terms of the ADSs to be issued in the Offering are EQUITY | Aug 11, 2026, 08:24 PM UTC M FOCL Proposes Public Offering FOCL proposes public offering of American Depositary Shares EQUITY | Aug 11, 2026, 08:22 PM UTC L FOCL - FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 FOCL - FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 EARNINGS | Jul 30, 2026, 09:00 PM UTC H FocalTherics Launches First European Commercial Endometriosis Focal One Program With Treatment Of Initial Patients In Toulouse, France The hospital launched their endometriosis Focal One program following the acquisition of the system with the intention of utilizing it for treating both deep infiltrating endometriosis and prostate cancer. This launch is EARNINGS | Jun 30, 2026, 11:35 AM UTC